GNFT

Genfit

--

--(--)

Market Open: --

--

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 2

consensus rating "Strong Buy"

Hanging Man

Bearish Abandoned Baby

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

--

Prev.Close

--

%Range

--

Turnover

--

Avg Vol(4W)

--

Market Cap

--

Div.Yield

--

P/E(TTM)

--

EPS(TTM)

--

Beta

--

Free Float

--

Shares Outstanding

--

%Turnover

--

P/E(DYN)

--

P/B

--

BVPS

--

High

--

Low

--

52 Week High

--

52 Week Low

--

About GNFT

Genfit S.A.

A late-stage biopharmaceutical company that develops therapeutic diagnostic solutions for metabolic liver-related diseases

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

03/27/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

159

Fiscal Year Ends

12-31

Website

www.genfit.fr

Security Type

Depository Receipts (Ordinary Shares)

Office address

Parc Eurasante, 885, avenue Eugene Avinee, 59120 Loos, France

Business

--

Introduction

Genfit S.A. is a late-stage clinical biopharmaceutical company dedicated to the discovery and development of innovative drug candidates and diagnostic solutions for metabolic and liver-related diseases, where there are considerable unmet medical needs. They are leaders in nuclear receptor-based drug discovery with a rich history of nearly 20 years and a strong scientific legacy.

Company Financials

EPS

GNFT has released its 2022 Q2 earnings. EPS was reported at -0.23, versus the expected 0.00, missing expectations. The chart below visualizes how GNFT has performed over recent quarters, highlighting trends in earnings surprises.